Atlas Bio Emerges From Stealth With $13.2 Million To Build AI Platform For In Silico Clinical Trials
· pulse2.com · popularity 18/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at pulse2.com →
Summary
Atlas Bio has emerged from stealth with $13.2 million in combined funding from Creandum, First Momentum Ventures, and LEA Ventures to develop an AI platform designed to predict how patients will respond to drugs before clinical trials begin. The post Atlas Bio Emerges From Stealth With $13.2 Million To Build AI Platform For In Silico Clinical Trials appeared first on Pulse 2.0 .
Found in: Pulse 2.0. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 12.